CaaMTech
CaaMTech is a pharmaceutical drug discovery company that creates and optimizes small-molecule, psychedelic-inspired therapeutics, including novel tryptamines, for mental health conditions. It studies how chemical structure relates to biological activity and screens compounds for safety and efficacy, aiming to develop medicines with desired effects and fewer unwanted side effects.
Facts
- HQ
- Issaquah, WA, US
- Sectors
- Pharmaceutical Manufacturing
- Founded
- 2019
- Employees
- 7
Is this your organization? Claim it
Seattle-area CaaMTech Raises $22M to Develop Novel Tryptamines, Aiming for Human Testing
Seattle-area startup CaaMTech raised $22 million to develop synthesized tryptamine compounds similar to those in psilocybin and LSD, aiming to create defined formulations that maximize desired psychedelic effects and minimize side effects. The company says many of its novel agents are unscheduled in the U.S., and it plans to advance toward human testing amid growing investment and interest in psychedelics for mental-health treatments.
People
-
Andrew Chadeayne Founder & CEO
-
Davis Wuolle Executive, Chief Technology Officer & Chief Marketing Officer
Online
Questions about CaaMTech
What is CaaMTech?
caam.tech
Who are the people behind CaaMTech?
Seattle Flow lists Andrew Chadeayne (Founder & CEO) and Davis Wuolle (Executive, Chief Technology Officer & Chief Marketing Officer) at CaaMTech.
Who invested in CaaMTech, and how much has it raised?
Members of Seattle Flow see CaaMTech's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is CaaMTech based?
CaaMTech is headquartered in Issaquah, WA, US.
When was CaaMTech founded?
CaaMTech was founded in 2019.
How many people work at CaaMTech?
CaaMTech has 7 employees.